Framework agreement for CAR-T cell therapy active ingredients
Originaltitel der Bekanntmachung
Italy – Antineoplastic and immunomodulating agents – GARA EUROPEA A PROCEDURA APERTA PER LA FORNITURA, IN ACCORDO QUADRO MULTIFORNITORE, DI PRINCIPI ATTIVI PER TERAPIE CON CELLULE CAR-T DESTINATE A PAZIENTI IN CARICO ALL’AZIENDA ULSS N. 8 BERICA
Opportunity Score
Warum diese Bewertung?
Chance
30 / 100
Komplexität
60 / 100
Risikofaktoren
The tender notice (XML) indicates the procedure is suspended due to a complaint (reclamo). Potential outcomes: cancella...
EU funding flag differs between structured data (EU-funded) and XML (no-eu-funds). Also, submission deadline time incon...
Tiefe Portfolioanalyse
Verwendet:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Eckdaten der Ausschreibung
- Öffentlicher Auftraggeber
- Azienda ULSS n. 8 Berica
- Land
- Italien
- CPV
- 33652000 - Antineoplastic and immunomodulating agents
- Frist
- Jul 06, 2026
- Geschätzter Wert
- EUR 19.4M
Überblick
Moderate opportunityWichtige Fakten
- EUR 19.4M estimated value
- Framework procurement
- Supplies contract
- 3 lots
- Duration 12 MONTH
- Supply of active principles (pharmaceutical substances) for CAR-T cell therapies.
- The products are intended for specific lymphoma indications: DLBCL (2nd and 3rd line), PMBCL (3rd line), and follicular lymphoma (4th line).
Vollständige Zusammenfassung anzeigen
This is an open procedure tender for a multi-supplier framework agreement for the supply of active principles for CAR-T cell therapies, intended for patients under the care of Azienda ULSS n. 8 Berica (Italy). The tender is divided into three lots covering specific lymphoma therapies. The procedure is currently suspended due to a complaint (reclamo) as per the XML notice. The estimated total value across lots is €19,401,945. Award is based solely on price. Submission deadline is 2026-07-06 (10:00 or 12:00 – inconsistency noted). Important documents (e.g., ESPD) are required. EU funding status is inconsistent between structured data (EU-funded) and XML notice (no EU funds). The notice is in Italian only.
Risiken
The tender notice (XML) indicates the procedure is suspended due to a complaint (reclamo). Potential outcomes: cancella...
EU funding flag differs between structured data (EU-funded) and XML (no-eu-funds). Also, submission deadline time incon...
Analyse kann unvollständig sein
Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.
Wichtige Anforderungen
Certifications
- All communications and submissions must be electronic via Sintel or certified email (PEC) for Italian operators, or qualified electronic registered delivery service for...
Administrative
- Registration on the Sintel e-procurement platform (ARIA SPA) is mandatory.
- Tender must be accompanied by the European Single Procurement Document (ESPD) or equivalent.
Anforderungen können unvollständig sein.
Zuschlagskriterien
Lot 1
Lot 2
Lot 3
Auftraggeber
Ort
Vicenza, ITA
Website
Auftraggeberprofil
Kennung
02441500242
Tätigkeit
Health
Lose (3)
LOT-0001
LOTTO 1 - Therapy for adult patients with DLBCL Lymphoma - 2nd Line and Therapy for adult patients with PMBCL Lymphoma - 3rd Line
Supply of active principles for CAR-T therapy for adult patients with DLBCL (2nd line) and PMBCL (3rd line). Framework agreement with a maximum value of €15,936,345, including a 12-month initial period and an optional 12-month renewal.
EUR 19.4M
Geschätzter Wert
Dauer
Kategorie
Zuschlagskriterien
Frist
Zuschlagsdetails
Lowest price
Hinweis zum Wert
Maximalwert der Rahmenvereinbarung
Originale TED-Daten anzeigen
Originaler Los-Titel
LOTTO 1 - Terapia per pazienti adulti con Linfoma DLBCL - 2 Linea e Terapia per pazienti adulti con linfoma PMBCL - 3 linea
Originale TED-Beschreibung
LOTTO 1 - Terapia per pazienti adulti con Linfoma DLBCL - 2 Linea e Terapia per pazienti adulti con linfoma PMBCL - 3 linea
LOT-0002
LOTTO 2 - Therapy for adult patients with DLBCL Lymphoma - 3rd Line
Supply of active principles for CAR-T therapy for adult patients with DLBCL (3rd line). Framework agreement with a maximum value of €1,732,800, including a 12-month initial period and an optional 12-month renewal.
EUR 19.4M
Geschätzter Wert
Dauer
Kategorie
Zuschlagskriterien
Frist
Zuschlagsdetails
Lowest price
Hinweis zum Wert
Maximalwert der Rahmenvereinbarung
Originale TED-Daten anzeigen
Originaler Los-Titel
LOTTO 2 - Terapia per pazienti adulti con Linfoma DLBCL - 3 Linea
Originale TED-Beschreibung
LOTTO 2 - Terapia per pazienti adulti con Linfoma DLBCL - 3 Linea
LOT-0003
LOTTO 3 - Therapy for adult patients with Follicular Lymphoma (FL) - 4th Line
Supply of active principles for CAR-T therapy for adult patients with follicular lymphoma (4th line). Framework agreement with a maximum value of €1,732,800, including a 12-month initial period and an optional 12-month renewal.
EUR 19.4M
Geschätzter Wert
Dauer
Kategorie
Zuschlagskriterien
Frist
Zuschlagsdetails
Lowest price
Hinweis zum Wert
Maximalwert der Rahmenvereinbarung
Originale TED-Daten anzeigen
Originaler Los-Titel
LOTTO 3 - Terapia per pazienti adulti con Linfoma follicolare (LF) - 4 linea
Originale TED-Beschreibung
LOTTO 3 - Terapia per pazienti adulti con Linfoma follicolare (LF) - 4 linea
Vergabedetails
- Veröffentlichungsdatum
- 02 Jul 2026
- Sprachen
- Italian
Referenzmetadaten
- Rechtsgrundlage
- 32014L0024
Referenz-IDs
- Ausschreibungs-ID
- 456933-2026
Dokumente (2)
Ähnliche Ausschreibungen
Opportunity Score
Warum diese Bewertung?
Chance
30 / 100
Komplexität
60 / 100
Risikofaktoren
The tender notice (XML) indicates the procedure is suspended due to a complaint (reclamo). Potential outcomes: cancella...
EU funding flag differs between structured data (EU-funded) and XML (no-eu-funds). Also, submission deadline time incon...
Tiefe Portfolioanalyse
Verwendet:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications